Minimizing toxicity in early-stage testicular cancer treatment

Expert Review of Anticancer Therapy

Volumn 12, Issue 2, 2012, Pages 185-193

  Singhera, Mausam ^a   Lees, Kathryn ^a   Huddart, Robert ^a   Horwich, Alan ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

adjuvant chemotherapy; adjuvant radiotherapy; follow up; surveillance; testicular cancer; treatment related toxicity

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GLUTATHIONE TRANSFERASE; PLATINUM COMPLEX;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COGNITIVE DEFECT; COMPARATIVE EFFECTIVENESS; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; EARLY CANCER; HUMAN; HYPERTENSION; HYPOGONADISM; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INTERSTITIAL PNEUMONIA; KIDNEY ARTERY STENOSIS; KIDNEY INJURY; LEUKEMIA; LUNG DISEASE; LYMPH NODE DISSECTION; METASTASIS; MICROALBUMINURIA; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORCHIECTOMY; OTOTOXICITY; PSYCHOSEXUAL DISORDER; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; REVIEW; RISK REDUCTION; SECOND CANCER; SEMINOMA; SENSORY NEUROPATHY; TESTIS CANCER; VASOSPASM;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; NEOPLASM STAGING; SEMINOMA; SURVIVAL RATE; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 84856837598     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.212     Document Type: Review

References (92)

1. Cancer Statistics Registrations: Registrations of cancer diagnosed in 2007. Office for National Statistics, UK (2010).
2. Power DA, Brown RS, Brock CS et al. Trends in testicular carcinoma in England and Wales, 1971-1999. BJU Int. 87, 361-365 (2001). (Pubitemid 32240850)
3. Toledano MB, Jarup L, Best N et al. Spatial variation and temporal trends of testicular cancer in Great Britain. Br. J. Cancer 84, 1482-1487 (2001). (Pubitemid 32579340)
4. Coleman MP, Rachet B, Woods LM et al. Trends in socioeconomic inequalities in cancer survival in England and Wales up to 2001. Br. J. Cancer 90, 1367-1373 (2004). (Pubitemid 38586262)
5. Meinardi MT, Gietema JA, van der Graaf WT et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J. Clin. Oncol. 18, 1725-1732 (2000). (Pubitemid 30220551)
6. Huddart RA, Norman A, Shahidi M et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J. Clin. Oncol. 21, 1513-1523 (2003). . First comparative paper on cardiovascular disease risk in long-term testicular cancer survivors. (Pubitemid 46594104)
7. van den Belt-Dusebout AW, Nuver J, de Wit R et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol. 24, 467-475 (2006). . Key confirmatory paper on cardiovascular disease risk. (Pubitemid 46630466)
8. Haugnes HS, Wethal T, Aass N et al. Cardiovascular risk factors and morbidity in long term survivors of testicular cancer: A 20-year follow-up study. J. Clin. Oncol. 28, 4649-4657 (2010).
9. Zagars GK, Ballo MT, Lee AK et al. Mortality after cure of testicular seminoma. J. Clin. Oncol. 22, 640-647 (2004). (Pubitemid 41095067)
10. Fossa SD, Aass N, Harvei S et al. Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br. J. Cancer 90, 607-612 (2004). (Pubitemid 38297198)
11. Fossa SD, Gilbert E, Dores GM et al. Noncancer causes of death in survivors of testicular cancer. J. Natl Cancer Inst. 99, 533-544 (2007). (Pubitemid 47073556)
12. van den Belt-Dusebout AW, de Wit R, Gietema JA et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol. 25, 4370-4378 (2007). (Pubitemid 350013842)
13. Robinson D, Moller H, Horwich A. Mortality and incidence of second cancers following treatment for testicular cancer. Br. J. Cancer 96, 529-533 (2007). (Pubitemid 46215229)
14. Nuver J, Smit AJ, van der Meer J et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J. Clin. Oncol. 20, 9130-9137 (2005).
15. Turlapaty PD, Altura BM. Magnesium deficiency produces spasms of coronary arteries: Relationship to etiology of sudden death ischemic heart disease. Science 208, 198-200 (1980). (Pubitemid 10072143)
16. Togna GI, Togna AR, Franconi M et al. Cisplatin triggers platelet activation. Thromb. Res. 99, 503-509 (2000).
17. Gietema JA, Meinardi MT, Messerschmidt J et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 355, 1075-1076 (2000). (Pubitemid 30162815)
18. Travis LB, Fossa SD, Schonfeld SJ et al. Second cancers among 40,576 testicular cancer patients: Focus on long term survivors. J. Natl Cancer Inst. 97, 1354-1365 (2005). .. Critical publication regarding second malignancy risk of testicular cancer survivors. (Pubitemid 41487803)
19. van den Belt-Dusebout AW, Aleman BM, Besseling G et al. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int. J. Radiat. Oncol. Biol. Phys. 75, 1420-1429 (2009).
20. Fossa SD, Horwich A, Russell JM et al. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomised trial. Medical Research Council Testicular Tumor Working Group. J. Clin. Oncol. 17, 1146 (1999).
21. Jones WG, Fossa SD, Mead GM et al. Randomised trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: A report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942. J. Clin. Oncol. 23, 1200-1208 (2005). (Pubitemid 46202277)
22. Zwahlen DR, Martin JM, Millar JL et al. Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma. Int. J. Radiat. Oncol. Biol. Phys. 70, 853-858 (2008).
23. Wanderas EH, Fossa SD, Tretli S. Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. Eur. J. Cancer 33, 253-262 (1997).
24. Travis LB, Holowaty EJ, Bergfeldt K et al. Risk of leukaemia after platinum-based chemotherapy for ovarian cancer. N. Engl. J. Med. 340, 351-357 (1999). (Pubitemid 29090800)
25. Tothill P, KLYS HS, Matheson LM et al. The long term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. Eur. J. Cancer 28A, 1358-1361 (1992).
26. Hartmann JT, Kollmannsberger C, Kanz L et al. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int. J. Cancer 83, 866-869 (1999).
27. Kollmannsberger C, Hartmann JT, Kanz L et al. Therapy-related malignancies following treatment of germ cell cancer. Int. J. Cancer 83 860-863 (1999).
28. Travis LB, Andersson M, Gospodarowicz M et al. Treatment-associated leukaemia following testicular cancer. J. Natl Cancer Inst. 92, 1165-1171 (2000).
29. Powles T, Robinson D, Shamash J et al. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann. Oncol. 19, 443-447 (2008). (Pubitemid 351336907)
30. Mykletun A, Dahl AA, Haaland CF et al. Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J. Clin.Oncol. 23 3061-3068 (2005). (Pubitemid 46224128)
31. Glendenning JL, Barbachano Y, Norman AR et al. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 116, 2322-2331 (2010).
32. Oldenburg J, Kraggerud SM, Cvancarova M et al. Cisplatin-induced long term hearing impairment is associated with specific glutathione-S-transferase genotypes in testicular cancer survivors. J. Clin. Oncol. 25, 708-714 (2007). (Pubitemid 350002927)
33. Peters U, Preisler-Adams S, Hebeisen A et al. Glutathione-S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 11, 639-643 (2000).
34. Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: An increasingly common developmental disorder with environmental aspects. Human Reprod. 16, 972-978 (2001). (Pubitemid 32451837)
35. Yeap BB. Testosterone and ill-health in aging men. Nat. Clin. Pract. Endocrinol. Metab. 5, 113-121 (2009).
36. Huddart RA, Norman A, Moynihan C et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br. J. Cancer 93, 200-207 (2005). (Pubitemid 41133206)
37. Lampe H, Horwich A, Norman A et al. Fertility after chemotherapy for testicular germ germ cell cancers. J. Clin. Oncol. 15, 239-245 (1997). . Important paper on fertility issues after chemotherapy. (Pubitemid 27020579)
38. Brydoy M, Fossa SD, Klepp O et al. Paternity following treatment for testicular cancer. J. Natl Cancer Inst. 97, 1580-1588 (2005). (Pubitemid 41662712)
39. Donohue JP, Foster RS, Rowland RG et al. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J. Urol. 144, 287-292 (1990).
40. Petersen PM, Hansen SW. The course of long-term toxicity in patients treated with cisplatin-based chemotherapy for non-seminomatous germ-cell cancer. Ann. Oncol. 10, 1475-1483 (1999). (Pubitemid 30017058)
41. Verheij M, Dewit LG, Valdes Olmos RA et al. Evidence for renovascular component in hypertensive patients with late radiation nephropathy. Int. J. Radiat. Oncol. Biol. Phys. 30, 677-683 (1994). (Pubitemid 24304480)
42. Mulla MG, Ananthkrishnan G, Mirza MS et al. Renal artery stenosis after radiotherapy for stage I seminoma, a case report. Clin. Oncol. 19, 209-211 (2007).
43. Fossa SD, Aass N, Winderen M et al. Long-term renal function after treatment for malignant germ-cell tumours. Ann. Oncol. 13, 222-228 (2002). (Pubitemid 34704973)
44. Sleijfer S. Bleomycin-induced pneumonitis. Chest 120, 617-624 (2001). (Pubitemid 32881285)
45. Haugnes HS, Aass N, Fossa SD et al. Pulmonary function in long-term survivors of testicular cancer. J. Clin. Oncol. 27, 2779-2786 (2009).
46. Dahl AA, Haaland CF, Mykletun A et al. Study of anxiety disorder and depression in long-term survivors of testicular cancer. J. Clin. Oncol. 23, 2389-2395 (2005). (Pubitemid 46218733)
47. Shinn EH, Basen-Engquist K, Thornton B et al. Health behaviours and depressive symptoms in testicular cancer survivors. Urology 69, 748-753 (2007). (Pubitemid 46574916)
48. Orre IJ, Fossa SD, Murison R et al. Chronic cancer related fatigue in long-term survivors of testicular cancer. J. Psychosom. Res. 64, 363-371 (2008). (Pubitemid 351417918)
49. Dahl AA, Bremnes R, Dahl O et al. Is sexual function compromised in long-term testicular cancer survivors? Eur. Urol. 52, 1438-1447 (2007). (Pubitemid 47445974)
50. Tuinman MA, Fleer J, Sleijfer DT et al. Marital and sexual satisfaction in testicular cancer survivors and their spouses. Support. Care Cancer 13, 540-548 (2005). (Pubitemid 40933612)
51. Rieker PP, Fitzgerald EM, Kalish LA. Adaptive behavioral responses to potential infertility among survivors of testis cancer. J. Clin. Oncol. 8, 347-355 (1990). (Pubitemid 20056569)
52. Schagen SB, Boogerd W, Muller MJ et al. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta. Oncol. 47, 63-70 (2008).
53. Warde P, Specht L, Horwich A et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: A pooled analysis. J. Clin. Oncol. 20, 4448-4452 (2002). .. Key paper on the use of surveillance in stage I seminoma including predictive factors. (Pubitemid 35334756)
54. Aparicio J, Diaz R. Management options for stage I seminoma. Expert Rev. Anticancer Ther. 10(7), 1077-1085 (2010).
55. Chung P, Mayhew LA, Warde P et al. Management of stage I seminomatous testicular cancer: A systematic review. Clin. Oncol. 22, 6-16 (2010).
56. Tandstad T, Smaaland R, Solberg A et al. Management of seminomatous testicular cancer: A binational prospective population-based study from the Swedish Norwegian testicular cancer study group. J. Clin. Oncol. 29, 719-725 (2011).
57. Oldenburg J, Martin JM, Fossa SD. Late relapses of germ cell malignancies: Incidence, management and prognosis. J. Clin. Oncol. 24, 5503-5511 (2006). (Pubitemid 46631330)
58. Dieckmann KP, Albers P, Classen J et al. Late relapse of testicular germ cell neoplasms: A descriptive analysis of 122 cases. J. Urol. 173, 824-829 (2005). (Pubitemid 40239350)
59. Wood L, Kollmannsberger, Jewett M et al. Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol. Assoc. J. 4, E19-E38 (2010).
60. Krege S, Beyer J, Souchon R et al. European Consensus Conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. Eur. Urol. 53, 497-513 (2008).
61. Aparicio J, Germa JR, Garcia del Muro X et al. Risk-adapted management for patients with clinical stage I seminoma: The Second Spanish Germ Cell Group study. J. Clin. Oncol. 23, 8717-8723 (2005). (Pubitemid 46211516)
62. Aparicio J, Maroto P, Garcia del Muro X et al. Risk-adapted treatment in clinical stage I testicular seminoma: The Third Spanish Germ Cell Cancer Group study. J. Clin. Oncol. 29, 4677-4681 (2011).
63. Oliver RT, Edmonds PM, Ong JY et al. Pilot studies 2 and 1 course carboplatin as adjuvant for stage I seminoma: Should it be tested in a randomized trial against radiotherapy? Int. J. Radiat. Oncol. Biol. Phys. 29, 3-8 (1994). (Pubitemid 24138858)
64. Oliver RT, Mason MD, Mead GM et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: A randomised trial. Lancet 366, 293-300 (2005). .. Key paper on the use of carboplatin in stage I seminoma. (Pubitemid 41019418)
65. Bosl GJ, Patil S. Carboplatin in clinical stage I seminoma: Too much and too little at the same time. J. Clin. Oncol. 29, 949-952 (2011).
66. Moynihan C, Norman AR, Barbachano Y et al. Prospective study of factors predicting adherence to medical advice in men with testicular cancer. J. Clin. Oncol. 27, 2144-2150 (2009).
67. van As NJ, Gilbert DC, Money-Kyrle et al. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: Optimising the detection of relapse. Br. J. Cancer 98, 1894-1902 (2008). . Evidence guidance on follow-up of germ cell tumors. (Pubitemid 351821555)
68. Martin JM, Panzarella T, Zwahlen DR et al. Evidence-based guidelines for following stage I seminoma. Cancer 109, 2248-2256 (2007). (Pubitemid 46801554)
69. Brenner DJ, Hall EJ. Computed tomography - an increasing source of radiation exposure. N. Engl. J. Med. 357, 2277-2284 (2007). (Pubitemid 350190758)
70. O'Malley ME, Chung P, Haider M et al. Comparison of low dose with standard dose abdominal/pelvic multidetector CT in patients with stage I testicular cancer under surveillance. Eur. Radiol. 20, 1624-1630 (2010).
71. Sohaib SA, Koh DM, Barbachano Y et al. Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin. Radiol. 64, 362-367 (2009).
72. Tolan S, Vesprini D, Jewett MA et al. No role for routine chest radiography in stage I seminoma surveillance. Eur. Urol. 57, 474-479 (2010).
73. Chung PW, Gospodarowicz MK, Panzarella T et al. Stage II testicular seminoma: Patterns of recurrence and outcome of treatment. Eur. Urol. 45, 754-760 (2004). (Pubitemid 38638396)
74. Classen J, Scmidberger H, Meisner C et al. Radiotherapy for stages IIA/B testicular seminoma: Final report of a prospective multicenter clinical trial. J. Clin. Oncol. 21, 1101-1106 (2003). (Pubitemid 46594140)
75. Krege S, Boergermann C, Baschek R et al. Single agent carboplatin for CSIIA/B testicular seminoma. A Phase II study of the German Testicular Cancer Study Group (GTCSG). Ann. Oncol. 17, 276-280 (2006). (Pubitemid 43160118)
76. Arranz Arija JA, Garcia del Muro X, Guma J et al. E400P in advanced seminoma of good prognosis according to the International Germ Cell Cancer Collaborative Group (IGCCCG) classification: The Spanish Germ Cell Cancer Group experience. Ann. Oncol. 12, 487-491 (2001). (Pubitemid 32472102)
77. Gilbert DC, Van As N, Beesley S et al. Treating stage IIA/B seminoma with combination carboplatin and radiotherapy. J. Clin. Oncol. 27, 2101-2102 (2009). . Description of stage IIA/B seminoma treatment with carboplatin and radiotherapy.
78. Read G, Stenning SP, Cullen MH et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J. Clin. Oncol. 10, 1762-1768 (1992). . Classic paper on the use of surveillance in stage I nonseminomatous germ cell tumors. (Pubitemid 23059954)
79. Vergouwe Y, Steyerberg EW, Eijkemans MJ et al. Predictors of occult metastasis in clinical stage I nonseminoma: A systematic review. J. Clin. Oncol. 21, 4092-4099 (2003). (Pubitemid 46606175)
80. Rustin GJ, Mead GM, Stenning SP et al. Randomised trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08. J. Clin. Oncol. 25, 1310-1315 (2007).
81. Harvey ML, Geldart TR, Duell R et al. Routine computerised tomographic scans of the thorax in surveillance of stage I testicular non-seminomatous germ-cell cancer-a necessary risk? Ann. Oncol. 13, 237-242 (2002). (Pubitemid 34704975)
82. Cullen MH, Stenning SP, Parkinson MC et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: A Medical Research Council report. J. Clin. Oncol. 14, 1106-1113 (1996). . Classic prospective study of adjuvant bleomycin, cisplatin and etoposide in high-risk stage I nonseminomatous germ cell tumors. (Pubitemid 26105516)
83. Albers P, Siener R, Krege S et al. Randomised Phase III trial comparing retroperitoneal lymph node dissection with one course of Bleomycin and etopside plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors. AUO trial AH 01/94 by the German Testicular Cancer Study Group. J. Clin Oncol. 26, 2966-2972 (2008). . Important comparison of retroperitoneal lymph node dissection outcomes with adjuvant chemotherapy.
84. Tandstad T, Dahl O, Cohn-Cedermark G et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: The SWENOTECA management program. J. Clin. Oncol. 13, 2122-2128 (2009).
85. Eberhard J, Stahl O, Cwikiel M et al. Risk factors for post-treatment hypogonadism in testicular cancer patients. Eur. J. Endocrinol. 158, 561-570 (2008).
86. Skoogh J, Steineck G, Stierner UK et al. Long-term cognitive function among testicular cancer survivors treated with chemotherapy. J. Clin. Oncol. 26, 258s (2008).
87. Sheinfeld J. Risks of the uncontrolled retroperitoneum. Ann. Surg. Oncol. 10, 100-101 (2003). (Pubitemid 40485926)
88. Heidenreich A, Albers P, Hartmann M et al. Complications of primary nerve-sparing retroperitoneal lymph node dissection on clinical stage I nonseminomatous germ cell tumors of the testis: : Experience of the German Testicular Cancer Study Group. J. Urol. 169(5), 1710-1714 (2003). (Pubitemid 36443478)
89. Gilbert DC, Chandler I, Summersgill B et al. Genomic gain and over expression of CCL2 correlate with vascular invasion in stage I non-seminomatous testicular germ-cell tumours. Int. J. Androl. 34, e114-e121 (2011).
90. Gilbert DC, McIntyre A, Summersgill B et al. Minimum regions of genomic imbalance in stage I testicular embryonal carcinoma and association of 22q loss with relapse. Genes Chromosomes Cancer 50(3), e186-e195 (2011).
91. Travis LB, Hill D, Dores GM et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J. Natl Cancer Inst. 97, 1428-1437 (2005). (Pubitemid 41520078)
92. Travis LB, Beard C, Allan JM et al. Testicular cancer survivorship: Research Strategies and Recommendations. J. Natl Cancer Inst. 102, 1114-1130 (2010).